These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27112529)

  • 1. Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
    Spratt DE; Osborne JR; Zumsteg ZS; Rebeiz K; Leeman J; Rivera A; Morris MJ; Zelefsky MJ
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):271-6. PubMed ID: 27112529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
    McKay RR; Silver R; Bhak RH; Korves C; Cheng M; Appukkuttan S; Simmons SJ; Duh MS; Taplin ME
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):210-219. PubMed ID: 32814846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
    McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
    Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
    Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
    Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Sartor O; Appukkuttan S; Weiss J; Tsao CK
    Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
    Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
    Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
    Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
    Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Boni G; Mazzarri S; Cianci C; Galli L; Farnesi A; Borsatti E; Bortolus R; Fratino L; Gobitti C; Lamaj E; Ghedini P; Rizzini EL; Massari F; Dionisi V; Fanti S; Volterrani D; Monari F
    Tumori; 2018; 104(2):128-136. PubMed ID: 29714668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway.
    Jarvis P; Ho A; Sundram F
    Nucl Med Commun; 2021 Mar; 42(3):332-336. PubMed ID: 33252512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Alva A; Nordquist L; Daignault S; George S; Ramos J; Albany C; Isharwal S; McDonald M; Campbell G; Danchaivijitr P; Yentz S; Anand A; Yu EY
    Prostate; 2017 Apr; 77(5):479-488. PubMed ID: 27990667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
    Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
    Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
    Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
    Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study.
    Frantellizzi V; Costa R; Mascia M; Spanu A; Farcomeni A; Licari M; Cindolo L; Nuvoli S; Pontico M; De Vincentis G
    Clin Genitourin Cancer; 2020 Jun; 18(3):185-191. PubMed ID: 32173355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
    Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
    Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Fong L; Morris MJ; Sartor O; Higano CS; Pagliaro L; Alva A; Appleman LJ; Tan W; Vaishampayan U; Porcu R; Tayama D; Kadel EE; Yuen KC; Datye A; Armstrong AJ; Petrylak DP
    Clin Cancer Res; 2021 Sep; 27(17):4746-4756. PubMed ID: 34108181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.
    Lu HH; Chiu NT; Tsai MH
    Ann Nucl Med; 2024 Jul; 38(7):508-515. PubMed ID: 38647876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.